SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
FORM 8-K/A |
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 24, 2017
(Exact name of registrant as specified in its charter)
_________________________
|
Florida |
1-13165 |
59-2417093 |
|
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (770) 419-3355
_____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
CryoLife, Inc. filed a Form 8-K with the Securities and Exchange Commission on July 25, 2017 (the “Original Filing”) to furnish a press release reporting its financial results for the quarter ended June 30, 2017. In the press release furnished with the Original Filing, there was a formatting error affecting the presentation of certain of the numbers in the press release. This Form 8-K/A is being filed to furnish a press release with updated formatting.
Section 9Financial Statements and Exhibits.
Item 9.01(d) Exhibits.
(a) Financial Statements.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions.
Not applicable.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1* |
Press release dated July 24, 2017 |
*This exhibit is furnished, not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CRYOLIFE, INC.
Date: August 10, 2017
|
By: |
/s/ Jean F. Holloway |
|
Name: |
Jean F. Holloway |
|
Title: |
Senior Vice President, General Counsel, Chief Compliance Officer and Secretary |
Exhibit 99.1
|
CryoLife |
The Ruth Group |
|
D. Ashley Lee |
Zack Kubow |
|
Executive Vice President, Chief Financial Officer and Chief Operating Officer |
646-536-7020 zkubow@theruthgroup.com |
|
Phone: 770-419-3355 |
CryoLife Reports Second Quarter 2017 Financial Results
Second Quarter Highlights:
|
· |
Revenues Increased Two Percent Year-over-Year to $47.8 Million; Non-GAAP Revenues Increased Four Percent Year-over-Year |
|
· |
Gross Margins were 69 Percent |
|
· |
GAAP Net Income was $3.2 Million, or $0.09 Per Fully Diluted Common Share; Non-GAAP Net Income was $4.0 Million, or $0.12 Per Fully Diluted Common Share |
ATLANTA, GA – (July 24, 2017) – CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the second quarter and first half of 2017.
Pat Mackin, Chairman, President, and Chief Executive Officer, said, “We had a solid second quarter and exceeded our guidance despite facing certain headwinds in the quarter. On-X, BioGlue and tissue processing all posted revenue growth. This was highlighted by another positive quarter for On-X, particularly in North America where On-X revenue grew 19 percent excluding the OEM business. In tissue processing, we delivered our second consecutive quarter of double-digit growth in cardiac tissue. During the quarter we also initiated the transition to direct sales in Canada, Belgium, the Netherlands and Luxembourg, further expanding our direct operations in Europe. We are on track to achieve our 2017 financial guidance and remain confident our strategy will continue to transform CryoLife into a higher growth, higher margin company.”
Revenues for the second quarter of 2017 increased two percent to $47.8 million, compared to $47.1 million for the second quarter of 2016. The increase was primarily driven by increases in tissue processing, BioGlue, On-X and TMR revenues, partially offset by the absence of HeRO revenues. Non-GAAP revenues for the second quarter of 2017 increased four percent compared to the second quarter of 2016. A reconciliation of GAAP to non-GAAP financial metrics is included as part of this press release.
Revenues for the first half of 2017 increased three percent to $92.9 million, compared to $90.1 million for the first half of 2016. The increase was primarily driven by increases in On-X, tissue processing and BioGlue revenues, partially offset by the absence of HeRO and ProCol
revenues, and a decrease in TMR revenues. Non-GAAP revenues for the first half of 2017 increased four percent compared to the first half of 2016. A reconciliation of GAAP to non-GAAP financial metrics is included as part of this press release.
GAAP net income for the second quarter of 2017 was $3.2 million, or $0.09 per fully diluted common share, compared to net income of $2.3 million, or $0.07 per fully diluted common share, for the second quarter of 2016. Non-GAAP net income for the second quarter of 2017 was $4.0 million, or $0.12 per fully diluted common share, compared to non-GAAP net income of $4.3 million, or $0.13 per fully diluted common share for the second quarter of 2016.
GAAP net income for the first half of 2017 was $5.4 million, or $0.16 per fully diluted common share, compared to net income of $4.9 million, or $0.15 per fully diluted common share, for the first half of 2016. Non-GAAP net income for the first half of 2017 was $7.2 million, or $0.21 per fully diluted common share, compared to non-GAAP net income of $7.6 million, or $0.23 per fully diluted common share for the first half of 2016.
With the exception of the income tax rate, the Company is reiterating its full year 2017 financial guidance, as summarized below, and expects revenues in the third quarter of 2017 to be between $46.5 million and $47.5 million.
|
2017 Financial Guidance Summary |
|
|
Total revenues |
$188 Million - $192 Million |
|
Product revenues |
Year-over-year mid-single digits % non-GAAP revenue increase |
|
Tissue processing revenues |
Year-over-year mid-single digits % revenue increase |
|
Gross margins |
Between 68% - 69% |
|
R&D expenses |
$17.0 Million - $19.0 Million |
|
Income tax rate |
Mid 10% |
|
Non-GAAP income per common share |
$0.40 - $0.43 |
All numbers in the table above are GAAP except where expressly referenced as non-GAAP. The Company does not provide GAAP income per common share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.
The Company’s financial guidance for 2017 is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company’s non-GAAP revenues
Page 2
include (as applicable) On-X revenues for the period in 2016 prior to the closing of the acquisition and excludes revenues for the HeRO Graft and ProCol product lines for 2016. The Company’s other non-GAAP results exclude (as applicable) business development expenses; gain on sale of business components; amortization expenses; and inventory basis step-up expense. The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions and the operating expense structure of the Company’s existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as new acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company does, however, expect to incur similar types of expenses in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast tomorrow at 8:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Mackin.
To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 8:00 a.m. A replay of the teleconference will be available July 25 through July 31, and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13665887.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include those regarding our financial guidance for 2017 and our ability to keep on track to achieve our 2017 financial guidance and to continue to build CryoLife into a higher growth, higher margin company. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include that the expected benefits of our focus on certain key initiatives may be incorrect or may not be achieved; we may not achieve the growth in core products that we expect; we may not continue to make progress at all or as quickly as we
Page 3
would like on certain items that negatively impacted the fourth quarter of 2016; we may not achieve the financial benefits of moving to direct sales channels in Canada, Belgium, the Netherlands, and Luxembourg and expanding our direct sales operations in Europe; and our business development efforts may not be successful. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2016, and our subsequent filings with the SEC. CryoLife does not undertake to update its forward-looking statements.
Page 4
CRYOLIFE, INC. AND SUBSIDIARIES
Financial Highlights
(In thousands, except per share data)
|
|
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
June 30, |
|
June 30, |
||||||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
||||
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
Products |
$ |
30,094 |
|
$ |
30,045 |
|
$ |
57,490 |
|
$ |
57,063 |
|
Preservation services |
|
17,724 |
|
|
17,038 |
|
|
35,387 |
|
|
33,036 |
|
Total revenues |
|
47,818 |
|
|
47,083 |
|
|
92,877 |
|
|
90,099 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products and preservation services: |
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
6,959 |
|
|
7,698 |
|
|
14,976 |
|
|
14,701 |
|
Preservation services |
|
7,954 |
|
|
9,084 |
|
|
15,484 |
|
|
17,476 |
|
Total cost of products and |
|
|
|
|
|
|
|
|
|
|
|
|
preservation services |
|
14,913 |
|
|
16,782 |
|
|
30,460 |
|
|
32,177 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
32,905 |
|
|
30,301 |
|
|
62,417 |
|
|
57,922 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
General, administrative, and marketing |
|
23,389 |
|
|
22,436 |
|
|
46,260 |
|
|
48,710 |
|
Research and development |
|
4,728 |
|
|
3,279 |
|
|
8,821 |
|
|
5,888 |
|
Total operating expenses |
|
28,117 |
|
|
25,715 |
|
|
55,081 |
|
|
54,598 |
|
Gain from sale of business components |
-- |
-- |
-- |
(7,915) | |||||||
|
Operating income |
4,788 |
4,586 |
7,336 |
11,239 | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
834 | 797 | 1,635 | 1,514 | |||||||
|
Interest income |
|
(55) |
|
|
(18) |
|
|
(95) |
|
|
(30) |
|
Other (income), net |
|
(134) |
|
|
(58) |
|
|
(91) |
|
|
(167) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
4,143 |
|
|
3,865 |
|
|
5,887 |
|
|
9,922 |
|
Income tax expense |
|
980 |
|
|
1,518 |
|
|
501 |
|
|
5,034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ |
3,163 |
|
$ |
2,347 |
|
$ |
5,386 |
|
$ |
4,888 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
0.09 |
|
$ |
0.07 |
|
$ |
0.16 |
|
$ |
0.15 |
|
Diluted |
$ |
0.09 |
|
$ |
0.07 |
|
$ |
0.16 |
|
$ |
0.15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
32,664 |
|
|
32,010 |
|
|
32,552 |
|
|
31,519 |
|
Diluted |
|
33,814 |
|
|
32,764 |
|
|
33,739 |
|
|
32,270 |
Page 5
CRYOLIFE, INC. AND SUBSIDIARIES
Financial Highlights
(In thousands)
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||
|
|
June 30, |
|
June 30, |
||||||||||||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
||||||||||
|
Products: |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
BioGlue and BioFoam |
$ |
16,683 |
$ |
16,187 |
$ |
32,364 |
$ |
31,503 | |||||||||
|
On-X |
9,862 | 9,554 | 18,722 | 16,269 | |||||||||||||
|
CardioGenesis cardiac laser therapy |
|
2,056 |
|
|
1,860 |
|
|
3,641 |
|
|
3,844 | ||||||
|
PerClot |
936 | 1,042 | 1,755 | 2,033 | |||||||||||||
|
PhotoFix |
557 | 490 | 1,008 | 871 | |||||||||||||
|
HeRO Graft |
|
-- |
|
|
912 |
|
|
-- |
|
|
2,325 | ||||||
|
ProCol |
|
-- |
|
|
-- |
|
|
-- |
|
|
218 | ||||||
|
Total products |
|
30,094 |
|
|
30,045 |
|
|
57,490 |
|
|
57,063 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Preservation services: |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Cardiac tissue |
|
8,477 |
|
|
7,548 |
|
|
15,979 |
|
|
13,976 | ||||||
|
Vascular tissue |
|
9,247 |
|
|
9,490 |
|
|
19,408 |
|
|
19,060 | ||||||
|
Total preservation services |
|
17,724 |
|
|
17,038 |
|
|
35,387 |
|
|
33,036 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Total revenues |
$ |
47,818 |
|
$ |
47,083 |
|
$ |
92,877 |
|
$ |
90,099 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
U.S. |
$ |
34,712 |
|
$ |
34,198 |
|
$ |
68,246 |
|
$ |
66,436 | ||||||
|
International |
|
13,106 |
|
|
12,885 |
|
|
24,631 |
|
|
23,663 | ||||||
|
Total revenues |
$ |
47,818 |
|
$ |
47,083 |
|
$ |
92,877 |
|
$ |
90,099 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
June 30, |
|
December 31, |
||||||||||||||
|
|
2017 |
|
2016 |
||||||||||||||
|
|
|
|
|
|
|
||||||||||||
|
Cash, cash equivalents, and restricted securities |
$ |
53,248 |
|
$ |
57,341 | ||||||||||||
|
Total current assets |
|
152,211 |
|
|
147,233 | ||||||||||||
|
Total assets |
|
322,221 |
|
|
316,140 | ||||||||||||
|
Total current liabilities |
|
25,771 |
|
|
30,102 | ||||||||||||
|
Total liabilities |
|
103,160 |
|
|
107,157 | ||||||||||||
|
Shareholders’ equity |
|
219,061 |
|
|
208,983 | ||||||||||||
Page 6
CRYOLIFE, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP
Net Income and Diluted Income per Common Share
(In thousands, except per share data)
|
|
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
June 30, |
|
June 30, |
||||||||
|
|
2017 |
|
2016 |
|
2017 |
|
2016 |
||||
|
GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
$ |
4,143 |
|
$ |
3,865 |
|
$ |
5,887 |
|
$ |
9,922 |
|
Income tax expense |
|
980 |
|
|
1,518 |
|
|
501 |
|
|
5,034 |
|
Net income |
$ |
3,163 |
|
$ |
2,347 |
|
$ |
5,386 |
|
$ |
4,888 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share: |
$ |
0.09 |
|
$ |
0.07 |
|
$ |
0.16 |
|
$ |
0.15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted-average common |
|
|
|
|
|
|
|
|
|
|
|
|
shares outstanding |
|
33,814 |
|
|
32,764 |
|
|
33,739 |
|
|
32,270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of income before income |
|
|
|
|
|
|
|
|
|
|
|
|
taxes, GAAP to net income, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes, GAAP |
$ |
4,143 |
|
$ |
3,865 |
|
$ |
5,887 |
|
$ |
9,922 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
Business development expenses |
|
1,094 |
|
|
1,067 |
|
|
1,382 |
|
|
6,635 |
|
Gain on sale of business components |
|
-- |
|
|
-- |
|
|
-- |
|
|
(7,915) |
|
Amortization expense |
|
1,141 |
|
|
1,156 |
|
|
2,283 |
|
|
2,118 |
|
Acquisition inventory basis step-up expense |
|
63 |
|
|
902 |
|
|
2,112 |
|
|
1,467 |
|
Income before income taxes, non-GAAP |
|
6,441 |
|
|
6,990 |
|
|
11,664 |
|
|
12,227 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense calculated at 38% normalized |
|
|
|
|
|
|
|
|
|
|
|
|
tax rate |
|
2,448 |
|
|
2,656 |
|
|
4,432 |
|
|
4,646 |
|
Net income, non-GAAP |
$ |
3,993 |
|
$ |
4,334 |
|
$ |
7,232 |
|
$ |
7,581 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of diluted income per |
|
|
|
|
|
|
|
|
|
|
|
|
common share, GAAP to diluted income per |
|
|
|
|
|
|
|
|
|
|
|
|
common share, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share, GAAP: |
$ |
0.09 |
|
$ |
0.07 |
|
$ |
0.16 |
|
$ |
0.15 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
Business development expenses |
|
0.03 |
|
|
0.03 |
|
|
0.04 |
|
|
0.20 |
|
Gain on sale of business components |
|
-- |
|
|
-- |
|
|
-- |
|
|
(0.24) |
|
Amortization expense |
|
0.03 |
|
|
0.03 |
|
|
0.07 |
|
|
0.06 |
|
Acquisition inventory basis step-up expense |
|
-- |
|
|
0.03 |
|
|
0.06 |
|
|
0.04 |
|
Tax effect of non-GAAP adjustments |
|
(0.02) |
|
|
(0.03) |
|
|
(0.07) |
|
|
(0.02) |
|
Effect of 38% normalized tax rate |
|
(0.01) |
|
|
-- |
|
|
(0.05) |
|
|
0.04 |
|
Diluted income per common share, |
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP: |
$ |
0.12 |
|
$ |
0.13 |
|
$ |
0.21 |
|
$ |
0.23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted-average common |
|
|
|
|
|
|
|
|
|
|
|
|
shares outstanding |
|
33,814 |
|
|
32,764 |
|
|
33,739 |
|
|
32,270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 7
CRYOLIFE, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP
Revenues; Gross Margin; General, Administrative, and Marketing
(In thousands, except per share data)
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||
|
|
June 30, |
|
June 30, |
||||||||||
|
|
2017 |
|
2016 |
Growth Rate |
|
2017 |
|
2016 |
Growth Rate |
||||
|
Reconciliation of total revenues, GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
to total revenues, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues, GAAP |
$ |
47,818 |
|
$ |
47,083 |
2% |
|
$ |
92,877 |
|
$ |
90,099 |
3% |
|
Plus: On-X pre acquisition revenues |
|
-- |
|
|
-- |
|
|
|
-- |
|
|
1,627 |
|
|
Less: HeRO revenues |
|
-- |
|
|
(912) |
|
|
|
-- |
|
|
(2,325) |
|
|
Less: ProCol revenues |
|
-- |
|
|
-- |
|
|
|
-- |
|
|
(218) |
|
|
Total revenues, non-GAAP |
$ |
47,818 |
|
$ |
46,171 |
4% |
|
$ |
92,877 |
|
$ |
89,183 |
4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||
|
|
2017 |
|
2016 |
|
|
2017 |
|
2016 |
|
||||
|
Reconciliation of gross margin %, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP to gross margin %, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues, GAAP |
$ |
47,818 |
|
$ |
47,083 |
|
|
$ |
92,877 |
|
$ |
90,099 |
|
|
Gross margin, GAAP |
$ |
32,905 |
|
$ |
30,301 |
|
|
$ |
62,417 |
|
$ |
57,922 |
|
|
Gross margin %, GAAP |
|
69% |
|
|
64% |
|
|
|
67% |
|
|
64% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin, GAAP |
$ |
32,905 |
|
$ |
30,301 |
|
|
$ |
62,417 |
|
$ |
57,922 |
|
|
Plus: Acquisition inventory basis step- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
up expense |
|
63 |
|
|
902 |
|
|
|
2,112 |
|
|
1,467 |
|
|
Gross margin, non-GAAP |
$ |
32,968 |
|
$ |
31,203 |
|
|
$ |
64,529 |
|
$ |
59,389 |
|
|
Gross margin %, non-GAAP |
|
69% |
|
|
66% |
|
|
|
69% |
|
|
66% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||
|
|
June 30, |
|
|
June 30, |
|
||||||||
|
|
2017 |
|
2016 |
|
|
2017 |
|
2016 |
|
||||
|
Reconciliation of general, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
administrative, and marketing, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expense, GAAP to general, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
administrative, and marketing, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expense, non-GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General, administrative, and marketing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expense, GAAP |
$ |
23,389 |
|
$ |
22,436 |
|
|
$ |
46,260 |
|
$ |
48,710 |
|
|
Less: Business development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
expenses |
|
(1,094) |
|
|
(1,067) |
|
|
|
(1,382) |
|
|
(6,635) |
|
|
General, administrative, and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
marketing expense, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
non-GAAP |
$ |
22,295 |
|
$ |
21,369 |
|
|
$ |
44,878 |
|
$ |
42,075 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 8